AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation

In this article

Pharma giant AstraZeneca will list on the New York Stock Exchange on Monday, days after it announced big commitments on the other side of the world.

Like the rest of Big Pharma, the company has a balancing act. It wants a close relationship with the U.S., its biggest market, and the listing is intended to boost investment there.

Meanwhile, innovation-friendly China is attracting pharma companies that urgently need to develop new medicines to replace the blockbuster drugs whose patents will expire within the next few years. Pricing challenges in the U.S. adds to the pressure.

AstraZeneca